Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
Authors
Keywords
-
Journal
JAMA Dermatology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2023-11-01
DOI
10.1001/jamadermatol.2023.4090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
- (2023) Xiaomei Leng et al. RMD Open
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- (2023) Peter C. Taylor et al. ADVANCES IN THERAPY
- Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)
- (2023) Antonio Torrelo et al. BRITISH JOURNAL OF DERMATOLOGY
- Baricitinib as the first systemic treatment for severe alopecia areata
- (2023) Colin M. Kincaid et al. Expert Review of Clinical Immunology
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- (2023) Brett King et al. LANCET
- The risk of venous thromboembolism in atopic dermatitis: a matched cohort analysis in UK primary care
- (2023) Richard B Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Cardiovascular Risk Management in Patients Treated with JAK Inhibitors
- (2023) Jill T. Shah et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate‐to‐Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo‐Controlled , Phase III Clinical Trial ( BREEZE‐AD4 )
- (2022) Thomas Bieber et al. BRITISH JOURNAL OF DERMATOLOGY
- The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis
- (2022) Jingsi Chen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- (2022) Brett King et al. NEW ENGLAND JOURNAL OF MEDICINE
- POS0519 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
- (2022) G. Karpouzas et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
- (2022) Kristian Reich et al. LANCET
- Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
- (2022) Christina Charles-Schoeman et al. ANNALS OF THE RHEUMATIC DISEASES
- Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
- (2022) Nathalie Conrad et al. LANCET
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
- (2022) David Rosmarin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
- (2022) Tai-Li Chen et al. JAMA Dermatology
- Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
- (2022) Thomas Bieber et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
- (2022) Norito Katoh et al. Dermatology and Therapy
- Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)
- (2021) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
- (2021) Brett King et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
- (2021) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cardiovascular Risk in Patients With Psoriasis
- (2021) Michael S. Garshick et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
- (2021) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
- (2021) Thomas Bieber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
- (2021) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
- (2021) Emma Guttman-Yassky et al. LANCET
- Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis
- (2021) Lawrence F. Eichenfield et al. JAMA Dermatology
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
- (2021) Andrew Blauvelt et al. JAMA Dermatology
- Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study
- (2021) Hidemi Nakagawa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
- (2020) Hidemi Nakagawa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Eric L Simpson et al. LANCET
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
- (2020) Jonathan I. Silverberg et al. JAMA Dermatology
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
- (2020) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis
- (2019) Aleksi J. Hendricks et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study
- (2018) Richard J Silverwood et al. BMJ-British Medical Journal
- Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study
- (2018) Richard J Silverwood et al. BMJ-British Medical Journal
- The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
- (2017) JianZhong Zhang et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unknown
- (2016) Research Synthesis Methods
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
- (2014) Alexis Ogdie et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study
- (2013) Wei-Sheng Chung et al. ANNALS OF THE RHEUMATIC DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now